REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children
Comparison of the Immunogenicity and Safety of a Combined Adsorbed Low Dose Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (REVAXIS®) With a Combined Diphtheria, Tetanus and Inactivated Poliomyelitis Vaccine (DT Polio®) When Given as a Booster Dose at 6 Years of Age
Primary objective:
To demonstrate the non inferiority between REVAXIS® and DT Polio® when given as a second booster to healthy 6 year-old children .
Secondary objectives:
- Additional immunogenicity assessments.
- To describe the safety profile of a single dose of REVAXIS® or DT-Polio®
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Albertville, France, 95880
-
Albi, France, 81000
-
Angers, France, 49100
-
Annecy, France, 74000
-
Anzin, France, 59410
-
Arras, France, 62000
-
Asnieres, France, 92600
-
Avion, France, 62210
-
Bassens, France, 33530
-
Bersee, France, 59235
-
Besancon, France, 25000
-
Blois, France, 41000
-
Boulogne, France, 92100
-
Brest, France, 29200
-
Broglie, France, 27270
-
Caen, France, 14000
-
Chalon-en-champagne, France, 51000
-
Champdeniers, France, 79220
-
Chigny Les Roses, France, 51500
-
Cholet, France, 49300
-
Claix, France, 38640
-
Clamart, France, 92141
-
Collombey Les Belles, France, 54170
-
Draguignan, France, 83300
-
Enghien-les-bains, France, 95880
-
Floirac, France, 33270
-
Frouard, France, 54390
-
Haguenau, France, 67500
-
Illkirch-graffenstaden, France, 67400
-
Issy Les Moulineaux, France, 92130
-
La Neuville Roy, France, 60190
-
Laon, France, 02000
-
Le Havre, France, 76600
-
Les Pieux, France, 50340
-
Louverne, France, 53950
-
Louvigne de Bais, France, 35680
-
Manduel, France, 30129
-
Marcq-en-barouel, France, 59700
-
Maromme, France, 76150
-
Marseille, France, 13004
-
Miniac Morvan, France, 35540
-
Montpellier, France, 34080
-
Montsang/orge, France, 91390
-
Morangis, France, 91420
-
Nancy, France, 54000
-
Nantes, France, 44300
-
Nogent Sur Marne, France, 94130
-
Ostwald, France, 67540
-
Paris, France, 75013
-
Paris, France, 75019
-
Plouzane, France, 29280
-
Poitiers, France, 86000
-
Pont A Mousson, France, 54700
-
Quimper, France, 29000
-
Rouen, France, 76000
-
Rouen, France, 76100
-
Saint Sebastien Sur Loir, France, 44230
-
Saint-ouen, France, 93400
-
Saint-raphael, France, 83700
-
Sanary Mer, France, 83110
-
Sevres, France, 92310
-
Strasbourg, France, 67000
-
Toulouse, France, 31000
-
Villemomble, France, 93250
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy child without chronic severe disease of either gender,
- 6 year-old child on vaccination day,
- Child previously vaccinated with three doses of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination within the first 6 months of life and a booster dose of a diphtheria, tetanus and poliomyelitis containing vaccine given alone or in combination at 16 - 18 months of life (±2 months),
- Consent form signed by both parents, or by the legal representative, properly informed about the study.
Exclusion Criteria:
- Child who had received less or more than 4 doses of a diphtheria, tetanus and/or poliomyelitis containing vaccine,
- Previous clinical or bacteriological diagnosis of diphtheria, tetanus or poliomyelitis,
- Child who had received any vaccine in the previous 30 days or with a vaccination scheduled during the course of the study,
- Child who present with immune impairment or humoral/cellular deficiency, neoplastic disease or depressed immunity,
- Child who had received within the previous 150 days or who will receive during the course of the study, any immunoglobulins or blood derived products,
- Child with true hypersensitivity to at least one of the components of a study vaccine or to streptomycin, neomycin or polymixin B,
- Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,
- Child who had presented severe hypersensitivity following an earlier immunization against diphtheria and/or tetanus,
- Known history of thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injection,
- Acute severe febrile illness and/or oral temperature ≥37.5°C at the time of vaccination
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: 2
|
|
|
EXPERIMENTAL: 1
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Neurologic Manifestations
- Neuromuscular Diseases
- Central Nervous System Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Neuromuscular Manifestations
- Actinomycetales Infections
- Enterovirus Infections
- Picornaviridae Infections
- Spinal Cord Diseases
- Clostridium Infections
- Hypocalcemia
- Calcium Metabolism Disorders
- Corynebacterium Infections
- Myelitis
- Tetanus
- Diphtheria
- Tetany
- Poliomyelitis
Other Study ID Numbers
Other Study ID Numbers
- F05-TdI-301
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.